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Natural health products (NHP) which include minerals, vitamins and herbal remedies are not generally considered
by medical practitioners as conventional medicines and as such are not frequently prescribed by health centre’s as
either main-line or supplemental treatments. In the field of cardiovascular medicine, studies have shown that
typically, less than half of patients suffering from coronary syndromes chose to take any form of NHP supplement
and these products are rarely recommended by their medical practitioner. Vascular/endothelial cell damage is a key
instigator of coronary arterial plaque development which often culminates in thrombosis and myocardial infarction
(MI). Current treatment for patients known to be at risk of primary or secondary (MI) includes lipid lowering statins,
anti-clotting agents (e.g. tissue plasminogen activator; tPA) and drugs for stabilization of blood pressure such as
beta-blockers. However, evidence has been building which suggests that components of at least several NHP (e.g.
aged garlic extract (AGExt), resveratrol and green tea extracts (GTE)) may have significant vascular protective effects
through reduction of oxidative stress, lowering of blood pressure, reduction in platelet aggregation, vasodilation
and inhibition of abnormal angiogenesis. Therefore, in this review we will discuss in detail the potential of these
substances (chosen on the basis of their potency and complimentarity) as anti-atherosclerotic agents and the
justification for their consideration as main-line additional supplements or prescriptions.
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According to a World Health Organization Fact Sheet
(EURO/03/06) cardiovascular disease (CVD) is the num-
ber one killer in Europe and world-wide, with heart dis-
ease and stroke being the major cause of death in all 53
Member States. It has in fact been described as a true
pandemic, with no respect for borders. Figures show that
34,421 (23% of all non-communicable diseases) of Eur-
opeans died from CVD in 2005. The report also high-
lighted the fact that there is approximately a 10-fold
difference in premature CVD mortality between Western
Europe and countries in Central and Eastern Europe (i.e.
there is a higher occurrence of CVD amongst the poor
and vulnerable). The problem for the European Union is
that there is a direct correlation between the premature* Correspondence: lbadimon@csic-iccc.org
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reproduction in any medium, provided the origdeath rate and the viability of countries’ economies. Al-
though improvements in understanding have helped to
reduce the number of Western European dying from
CVD and related diseases further advances will require a
clearer understanding of the pathobiological mechanisms
responsible for the development of atherosclerosis and
myocardial infarction. Approximately 75% of acute cor-
onary events are associated with disruption of athero-
sclerotic plaques, development of which takes place over
several decades of life, (early vessel damage beginning
during child-hood) and whose susceptibility to instability
and thrombosis is largely dependent on a number of
known risk-factors (dyslipidemia, arterial hypertension,
hyperglycaemia and diabetes) [1].Key features of coronary atherosclerotic plaque
development
In the early stages of vessel damage prior to plaque for-
mation, chronic minimal injury caused by sheer stresstd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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tional changes leads to intraluminal endothelial damage
and dysfunction. Concomitantly, pro-inflammatory intra-
cellular signalling pathways are recruited which lead to
transcriptional up regulation of expression of growth fac-
tors (e.g. vascular endothelial cell growth factor, platelet-
derived growth factor and fibroblast growth factor-2)
cytokines (e.g. tumour necrosis factor-alpha and MCP-
1), adhesion molecules (e.g. intracellular adhesion mol-
ecule-1 and vascular endothelial cell adhesion molecule)
and chemoattractant proteins [2]. Endothelial cell dam-
age, activation and up-regulation of adhesion molecules
encourage the attraction of platelets, T-cells, and macro-
phages which engulf excess cholesterol transform into
foam cells and help to produce fatty streaks-some of the
earliest pathological sign of plaque development [3].
Endothelial dysfunction is known to impair the produc-
tion and bioavailability of nitric oxide (protective against
atherosclerosis) and therefore protection of these cells
against damage and/or increasing the circulating nitric
oxide levels using pharmacological agents could have
clinical benefit for high risk candidates [4,5].
As more platelets and immune cells aggregate at a
damaged region, the increased cytokine production leads
to local cellular proliferation, and transmission of activat-
ing signals to the adventitial vasa vasorum which become
activated and migrate through the layers of the artery to
help feed the now growing plaque [6,7].
Actively growing plaques often remain stable with thick
fibrous caps and contain a high proportion of smooth
muscle cells. In these cases, arterial remodelling eventually
results in a gradual narrowing of the lumen resulting in,
patient symptoms such as angina. The mechanisms re-
sponsible for determination of the development of vulner-
able unstable plaques rather than stable ones is still
unknown although there is evidence for the involvement
of a number of key factors, namely, oxidative stress and
formation of oxidized low density lipoproteins, diabetes,
high or fluctuating blood sugar levels and formation of
advanced glycation end-products (AGEs), the process of
inflammation and tumour-like angiogenesis.
The importance of plaque vascularisation
Plaque angiogenesis is now accepted to have a fundamen-
tal role in the pathophysiological development of athero-
sclerosis, providing nutrients to the developing and
expanding intima and also potentially creating an unstable
haemorrhagic environment prone to rupture. The expres-
sion of intimal neovessels is directly related to the stage of
plaque development, the presence of symptomatic disease
and the risk of plaque rupture. In atherosclerosis, intimal
neovascularization arises most frequently from the dense
network of vessels in the adventitia, adjacent to a plaque,
rather than from the main artery lumen. The irregularnature of blood vessel formation has been likened to
tumour angiogenesis, and hence the factors responsible
for their growth may be different from those seen during
normal wound healing. Our previous studies and those of
others have suggested that haemorrhagic, leaky blood ves-
sels from unstable carotid plaques proliferate abnormally.
These relatively large caliber but immature neovessels are
poorly invested with smooth muscle cells and possess
structural weaknesses which may contribute to instability
of the plaque by facilitation of inflammatory cell infiltra-
tion and haemorrhagic complications Therefore; inhibition
of angiogenesis might be an important target for preven-
tion of development of active, unstable plaque lesions [7].
Oxidative stress
The process of oxidative stress starts early in developing
lesions, when inflammatory cells and/or dysfunctional
mitochondra caught in the arterial wall begin to secrete re-
active oxygen species (ROS) [8]. ROS are able to stimulate
cellular apoptosis directly, and also to oxidize low-density
lipoproteins (LDLs) [9]. Oxidised LDLs (oxLDLs) promote
smooth muscle cell and macrophage gelatinase production
as well as stimulating pro-inflammatory signalling pathways
through tissue factor (TF), interferon regulatory factor-1
(IRF-1) and Toll-like receptor-2 (TLR2), thereby contribut-
ing significantly to plaque instability and thrombosis [10].
Similarly, particularly in diabetic patients, a combination of
chronic hyperglycaemia and enhanced oxidative stress
results in production and deposition of advanced glycation
end-products (AGEs) in the coronary arteries, which acti-
vate intracellular processes through their receptor receptor
for AGEs) (RAGE) inducing further oxidative stress, pro-
moting inflammation via NFkappaB, and increasing ECM
accumulation [11]. Reduction of plaque inflammation and
oxidative stress could help to prevent plaque erosion and
ultimately thrombosis.
Current preventative and treatment strategies for
CAD
Throughout Europe and the EU, patients recognized by
general practitioners and within hospitals to be at risk of
developing coronary artery disease (CAD) (genetic profiles,
risk factor analysis, presence of symptomatic disease etc.)
or with a known history of CAD, may be offered a variety
of prescriptions designed to reduce the risk of first or sub-
sequent MI. Aspirin and other anti-platelet medicines such
as clopidogrel help to prevent blood clots, whilst new anti-
platelet agents including prasugrel and ticagrelor have
shown reduced iscaemic efficacy and greater safety for
patients with acute coronary syndromes (ACS) [12]. Statins
(inhibitors of HMG-CoA) are commonly prescribed to
patients presenting with high total cholesterol levels or
high HDL/LDL ratios when one or more related risk fac-
tors are also present. Rosuvastatin, one of the more
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beneficial, preventative actions (greater than other statins)
besides its lipid-lowering ability for patients with CAD.
Rosuvastatin has been shown to preserve coenzyme Q10,
ubiquinol and concomitantly increase HDL-C levels [13]
significantly induce plaque regression by reducing plaque
volume [14], and reduced vascular endothelial cell growth
factor (VEGF) levels following myocardial revascularization
potentially reducing plaque neovascularisation [15]. Beta
(adrenoceptor antagonists)-blockers and calcium-channel
blockers, reduce chronic resting heart-rate (an independent
predictor of CAD mortality) and reduce blood pressure/
hypertension, possibly the most important single factor
associated with CAD [16], whilst angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II receptor
blockers also reduce blood pressure and may also have a
protective effect against development of atherosclerosis by
ameliorating endothelial dysfunction [17].
Limitations of current treatments
Limitations of the current treatments are clear, side-effects
and long-term complications apart, the known effects of
these medications show only marginal interactions with
some of the major processes known to be responsible for
creation of unstable plaques i.e. oxidative stress combined
with inflammation and angiogenesis (with the possible ex-
ception of some types of statin which is the subject of on-
going research). As well as this, a significant amount of
evidence exists that patients with none-acute cardiac dis-
ease are markedly more unlikely to receive guideline-
recommended therapy [18]. Hence, the majority of at-risk
individuals currently only start medication after the onset
of symptoms at which time plaque development and arter-
ial remodelling is evident or has already occurred.
Current use of NHP in clinical practice
Diet has long been known to be a modifiable risk factor
for CHD with Mediterranean diets and consumption of
fish, fruit and whole grain all having beneficial effects
[19]. People with diets containing high levels of sub-
stances, with anti-oxidant properties, such as vitamins E
and C, and beta-carotene, tend to live longer and more
healthily. A search through PubMed using the terms
“natural health products” and “CAD” reveals only 21
hits, one of the most recent by Shukla et al. [20], describ-
ing profound cardiovascular protective effects of nutri-
tional supplements such as flavonoids, olive oil,
lycopene, resveratrol and soy in epidemiological and clin-
ical studies. A far more interesting picture is seen when
examining individual substances by literature analysis
(see below). Most importantly, a recent study by Alherb-
ish et al. [21] who conducted a survey on patients admit-
ted with acute vascular disease, discovered that a wide
variety of NHPs are used by patients including vitaminsand minerals (73%), herbal products (20%) and amino
acids/essential fatty acids etc. (35%), however, the health
professionals themselves rarely included NHPs as part of
their medication profile.
Evidence for the protective properties of AGExt,
Resveratrol and GTE in CVD
Very few studies have analyzed in detail or retrospect-
ively compiled data by systematic analysis, on the effects
of dietary supplements on arterial disease. One such
study examined 38 published studies (clinical trials)
examining the effects of NHPs on arterial stiffness mea-
sured by pulse-wave velocity [22]. The results showed
that in a majority of trials, omega-3 supplementation,
isoflavones, and flavonoids produced significant reduc-
tions in arterial stiffness. There was insufficient data no
make conclusions in respect of other substances includ-
ing herbal medicines, and garlic. Here we will focus on
analysis of the data concerning three key substances to
provide evidence of their potential cardio-vascular pro-
tective effects.
Evidence for the protective properties of AGExt
In vitro studies have demonstrated that AGExt and in par-
ticular its most active components, the water-soluble cystei-
nyl moieties S-allylcysteine and S-allylmercaptocysteine are
exceptionally powerful anti-oxidant phytochemicals, protect-
ive against oxidative stress (by scavenging reactive oxygen
species and increasing superoxide dismutase levels) and in-
hibition of subsequent cellular damage [23,24]. AGExt was
shown to suppress CD36 scavenger receptor expression on
macrophages, decrease binding of nuclear proteins to a
PPARγ pathway, and inhibit Dil-labelled OXLDL uptake
[25]. Similarly, black AGExt demonstrated anti-inflammatory
properties when administered to human umbilical vein
endothelial cells (HUVEC) by preventing tumour necrosis
factor-alpha (TNFα)-induced expression of adhesion mole-
cules (VCAM-1 and ICAM-1) and inhibiting NF-κB tran-
scription factor expression as well as reducing monocyte
adhesion and ROS generation [26,27]. Hence in vitro studies
demonstrate a potential use for AGExt (which has no spe-
cific side-effects and can be taken in high potentially
pharmacologically effective doses) in reducing oxidative
stress, inflammation, and providing endothelial protection
against sheer stress damage. Can these effects prove translat-
able in vitro? Very few studies have investigated interactions
between AGExt and pharmacologically active substances
used to treat patients with CVD, although there are not
thought to be any particular negative synergistic effects [28].
In 2009, Budoff et al. [29] conducted a randomized clinical
trial to assess if AGExt could retard the progression of sub-
clinical atherosclerosis. 65 patients were treated for one year
with AGExt (250 mg) together with vitamin supplements
daily. After one year, patients receiving the AGExt showed
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reactivity (measured by temperature rebound). Total choles-
terol, homocysteine, MDL-LDL auto-antibodies and apoB-
immune complexes were decreased whilst HDL, apoB and
Lp (a) were all significantly increased. In conclusion, this is
the first study to demonstrate improvement in oxidative
markers, vascular function and a significant reduction in the
progression of atherosclerosis in association with dietary
AGExt supplementation in humans.
AGExt also reduced blood pressure (960 mg/day; sys-
tolic BP reduced by 10.2 mmHg; p = 0.03) [30], and
inhibited production of AGEs and glycation-induced
cross-linking in vitro [31] Figure 1. AGEs, produced by
chronic exposure of proteins to high sugar levels are par-
ticularly prevalent in patients with diabetes. When they
bind to the receptor for AGEs (RAGE), they activate cel-
lular signalling pathways associated with inflammation,
generation of oxidative stress and ROS and are asso-
ciated with premature development of atherosclerotic
diabetic lesions, rich in leukocyte infiltrates [32,33].
Components of AGExt (N-acetylcysteine) and AGExt it-
self have been shown to reduce expression of RAGE,
endothelial cell adhesion molecules, NF-κB, MDA, ROS
generation and matrix metalloproteinases culminating in
plaque stabilization in apoE-deficient mice [34].
Resveratrol has strong anti-oxidative and anti-inflammatory
properties
Trans-resveratrol, a polyphenol, and the major grapevine
phytoalexin (3,5,4´-trihydroxystilbene; Figure 2) has
attracted a lot of attention in the last couple of years due
to its extremely potent anti-oxidative and anti-inflamma-
tory capacity and its potential use in the treatment of
vascular disease and prevention or attenuation of athero-
sclerosis [35]. This group of anti-oxidants is thought to
be responsible for the ‘French paradox’ where a low mor-
tality rate for CAD exists in the population despite their
diet of high fat and smoking [36]. In vitro and in vivoFigure 1 A, AGExt (0–56 mg/ml) inhibition of dimer and trimer produ
in vitro for 21 days (c-h; 0, 7, 14, 28, 42, 56 mg/ml). B, Lysozyme incub
35 days and the effect of 0, 7, 14, 28, 42, 56, 70 and 84 mg/ml of AGExt on
trimer formation in the presence of AGExt.studies have identified a multitude of potentially protect-
ive effects of this compound. For example, Balestrieri
et al., [37], demonstrated that resveratrol or indeed red
wine alone could significantly prevent TNF-α-induced
reduction in endothelial cell progenitor (EPC) cell num-
ber at physiological concentrations which could posi-
tively impact on re-endothelization of damaged vessels.
Resveratrol was also shown to block Ca2+ influx in
thrombin-stimulated platelets and to block ADP, colla-
gen and thrombin induced platelet aggregation through
a pathway which may involve inhibition of thromboxane
A2 [38]. Similarly, resveratrol was shown to inhibit
human platelet aggregation stimulated by collagen and
concomitantly induce platelet apoptosis through activa-
tion of caspases-9, 3, and 8 as well as gelsolin and actin
cleavage [39]. Prevention of aggregation coupled with
apoptosis may represent an important mechanism for re-
duction in thrombotic events.
Resveratrol also inhibited both endothelial cell migra-
tion and MCP-1-induced monocyte cell chemotaxis,
which could potentially reduce neointimal vascularisa-
tion and monocyte recruitment into a growing plaque
[40]. Regarding inflammation, roscovitine is a potent in-
hibitor of NF-κB activation, other inflammatory gene ex-
pression (e.g. IL-6, IL-8), endothelial cell adhesion
molecule expression including ICAM-1 and monocyte
adhesiveness to endothelial cells (and recruitment into
the artery wall) in an Akt-dependent manner [35,41].
Resveratrol also inhibits cyclooxygenase and hydroperox-
idase functions thereby reducing inflammation even
more potently [42]. Using an apoE knockout mouse
model, Norata et al. [43] showed that animals fed with a
supplement containing cathechin, caffeic acid and resver-
atrol, had significantly smaller plaques after 8 weeks
(36–40%) in the aortic sinus and ascending aorta mainly
due to a reduction in inflammatory infiltration and ex-
pression of MCO-1, MIP-1α, MIP-1β, CCR1, CCR2 and
ET1 in the vascular wall. Similarly, Kim et al. [44]ction in BSA exposed to high glucose (0.5 M; a-b, controls)
ated in the absence (lane a) or presence of 0.5 M glucose (b–i) for
dimerization. Arrows indicate a significant reduction in dimmer and
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Figure 2 Schematic showing the structure of resveratrol and some of its most potent effects on intracellular signalling associated with
prevention of EC activation and unstable plaque development. Its potent anti-oxidant, anti-inflammatory and EC protective effects are
included here and are thought to be the main reason for its cardio-protective effects and ability to inhibit plaque de-stabilization.
Slevin et al. Vascular Cell 2012, 4:9 Page 5 of 9
http://www.vascularcell.com/content/4/1/9showed that oral administration of resveratrol sup-
pressed intimal hyperplasia in a wire-injured femoral ar-
tery mouse model. Their further examination of cultured
smooth muscle cells revealed inhibition of PDGF-
induced ROS and cell proliferation as well as increased
expression of Nrf2 and anti-oxidant response element re-
porter activity associated with HO-1 induction. This data
was in agreement with work performed by Brito et al.,
[45], who showed that resveratrol could inhibit oxLDL-
induced smooth muscle cell proliferation via inhibition
of the PI3K/Akt/mTOR/p70S6K pathway.
Endothelial cell function is known to be improved in the
presence of resveratrol through potentiation of endothelial
NO synthase (eNOS) via activation of PPARα and SIRT1 in
vascular endothelial cells and diabetic rats in vivo [38,46].
In monocytes from diabetic patients resveratrol, counter-
acted the pro-atherosclerotic effects of high glucose levels
by reducing super-oxide production through activation of
mitochondrial signalling pathways involving SIRT1-FOXO.
E-selectin was also down-regulated [47]. Studies with type-
1 diabetic rats have shown that treatment with resveratrol
(10 mg/kg) prevented impairment in eNOS and nNOS-
dependent vasodilation in cerebral blood vessels. eNOS
and nNOS were also increased whilst super-oxide dismu-
tase was reduced suggesting a restorative function for vas-
cular tissue and oxidative stress [48]. Nitric oxide regulates
vascular tone, causes endothelium-dependent vasodilation,
and decreases platelet aggregation. In addition it acts as an
anti-oxidant, anti-proliferative and anti-inflammatory mol-
ecule giving it a key role in the inhibition/prevention of
atherosclerosis [49]. A multitude of studies have also showna significant reduction in oxidative stress in a variety of car-
diovascular-implicated cells including blood mononuclear
cells (decreased malondialdehyde concentration), human
platelets (reduction in peroxynitrite-induced oxidation),
super-oxide scavenging in damaged rat myocardial tissue
and inhibition of LDL oxidation ([50] for a review).
Other studies show the enormous potential clinical
applications of this compound from demonstrations of its
complete lack of toxicity in humans even at high doses, to
its lipid lowering capability in mammalian models and
general ‘reduction in modifiable risk factors’ [51,52] and
protection of cardiomyocytes against apoptosis [53].
Flavanols and other compounds in green and black tea
extracts
Green and black tea and green and black tea extracts are a
potent source of flavanols (catechins), phenolic acids and
flavonoids, with the catechin (−)-epigallocatechin-3-gallate
(EGCG; Figure 3) perhaps being the most abundant [54].
Studies have shown that these substances delivered as an
extract from de-caffeinated tea (455 mg/day) could reduce
hemodialysis-induced ROS generation and pro-inflamma-
tory cytokine expression in patients [55]. Cross-sectional,
randomized controlled and prospective population studies
have shown that tea intake and/or increased dietary tea fla-
vonoids reduced the risk of cardiovascular disease, with
consistent data demonstrating enhancement of NO pro-
duction and concomitant improvement of endothelial
function as well as reduction in total cholesterol levels and
LDL cholesterol [56]. In one particular population-based
prospective cohort study, (the Ohsaki study), 40,530
Figure 3 Representative diagrams showing the interaction between EGCG and important signalling pathways associated with nuclear
response gene activation and subsequent inflammation and oxidative stress. Key: EGFR, Endothelial Growth Factor Receptor; ROS, Reactive
Oxygen Species; IGF-1R, Insulin Growth Factor-1 Receptor; PAI-1, Plasminogen Activator Inhibitor-1; NF-κB, Nuclear Factor-kappa-B; FAK, Focal
Adhesion Kinase.
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demonstrated an inverse relationship between CVD mor-
tality and tea consumption [57]. Ras et al. [58] showed by
meta-analysis of nine studies that tea consumption was dir-
ectly associated with increased (40%) flow-mediated dila-
tion of the brachial artery (a measurement of endothelial
function), and Tinahones et al., [59] using the same meth-
odology also showed concomitant reduction in oxLDL
levels in patients taking green tea extract supplements
demonstrating potential protection against CVD.
These polyphenols were also shown to significantly re-
duce serum glucose and lipid peroxidation levels in alloxan
diabetic rats [60]. In vivo studies have shown that these
green tea extracts appear to have insulin-like activities, with
EGCG inhibiting intestinal glucose uptake via the sodium-
dependent glucose transporter SGLT1 [61]. In vitro, tea
extracts were shown to inhibit endothelial cell plasminogen
activator inhibitor-1 (PAI-1; inhibits fibrinolysis and
increases the risk of thrombolysis) through a pathway in-
volving PI-3 K/Akt, again, suggesting they may contribute
to cardiovascular protection [62]. Other studies have
demonstrated that green tea extracts reduced plasma trigly-
cerides, insulin resistance and oxidative stress in insulin-
resistant Wistar rats which suggests a potential protective
role against diabetes-associated premature development of
CVD in patients [63].Should NHP be prescribed as main-line drugs and/
or supplements for patients at risk of MI?
A substantial amount of data including that provided
above strongly suggests that either alone or possibly in
combination (in the form of a super pill), substances
derived from natural health products such as EGCG,
resveratrol and s-allylcysteine, may have important car-
diovascular health benefits. Although much of the data
is based on work carried out in vitro (mostly to deter-
mine mechanisms of action) and using animal models, a
significant amount of recently reported data from clin-
ical trials now suggests these products prescribed alone
or in combination may prove to be important alternative
or additional main-line prescription drugs. Many of
these bioactive phytochemicals have synergistic effects
making multi-extract combinations more efficient for
targeting more than one target and also meaning that
lower oral doses can be used. For example, Baile et al.
[64] demonstrated that a mixture including resveratrol
and quercetin was able to reduce adipogenesis in ovar-
iectomized rats, and a number of studies have showed
increased anti-tumour activity of polyphenolic mixtures.
However, so far, there are very few studies examining
the potential benefits of these mixtures in protection
against or amelioration of CAD and secondary
complications.
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in vitro studies, in vivo models of disease and retrospective
studies strongly suggest that polyphenol-rich products
could have beneficial effects, and that circulating markers
of CVD such as oxLDL, total anti-oxidant capacity, F2-iso-
prostanes and ox-LDL) are often reduced, prospective
studies are lacking, and causal relationships have not yet
been reliably found. The authors go on to suggest that a
direct effect of these bioactive compounds is highly un-
likely as metabolism during ingestion would result in lower
serum circulating levels than those of other existing anti-
oxidants. Furthermore, much more detailed work needs to
be applied to understanding fully the mechanisms of action
of these substances and how each interacts with the most
important factors (inflammation, oxidative stress, angio-
genesis, diabetes and hypertension) associated with early-
medium levels of arterial damage, plaque development and
ultimately symptomatic CAD. Smoliga et al., [66] describes
using resveratrol as an example the lack of understanding
of pharmokinetics of this compound in human metabol-
ism, long-term toxicity studies and drug-drug interactions,
all of which must be established prior to consideration or
justification of its use in routine clinical practice. The situ-
ation would become even more complex in the design of a
super pill composed of several ingredients targeting more
than one anti-atherosclerotic pathway. In vitro studies
demonstrated that higher doses of EGCG were toxic to rat
hepatocytes (100–500 μg/ml) and caused pancreatic β-cell
damage in streptozotocin-induced diabetic rats (5 mg/kg/
day) [67,68], confirming the importance of further studies.
Nevertheless, the striking potential benefits of the
three substances we have reviewed as well as others ori-
ginating from for example soy, olive oil and cocoa should
be continued to be investigated, with justification, as the
world of vascular biology and in particular the devastat-
ing disease of atherosclerosis is desperately in need of
identification and approval of novel therapeutics. There-
fore, at the present time this group of natural product-
derived substances may represent the best new pharma-
cological preventative/protective treatment strategy. So
far, the numbers of in vivo studies examining the active
ingredients of these substances are still limited, the
major active molecules remain to be identified and syn-
ergistic effects studied in detail before we are ready to
contemplate realistic clinical trials in association with
detailed comparisons with existing pharmacological
agents used for treatment of the major CAD/cerebrovas-
cular risk factors.
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